CIK 0001662774
- Non-accelerated filer
- Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 901024039
- Phone
- +1 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- 4 Open-market buy Director bought 50,000 shares at $33.77 ($1,688,500)
- 4 Gift Director gave 1,534,720 shares (gift)
- 4 Open-market sale Chief Executive Officer sold 30,000 shares at an average $35.59 ($1,067,611)
- 4 Open-market buy Director bought 50,000 shares at an average $35.34 ($1,767,057)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Executive Officer sold 60,000 shares at an average $38.49 ($2,309,600)
- 5 Insider Annual Insider Trading Report
- 4 Open-market sale Executive Vice President sold 40,000 shares at an average $30.81 ($1,232,528)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion Executive Vice President acquired 3,500 shares (option exercise)
- 4 Open-market buy IA/Managing Member of 10% Owne bought 9,040 shares at an average $44.25 ($400,018)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 8 of 11 · 211 filings